Jian Lu1, Ming Zhao2,3, Yasuaki Arai4, Bin-Yan Zhong5, Hai-Dong Zhu1, Xiao-Long Qi6, Thierry de Baere7, Uei Pua8, Hyun Ki Yoon9, David C Madoff10, Gao-Jun Teng1. 1. Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China. 2. State Key Laboratory of Oncology in Southern China, Guangzhou, China. 3. Minimally Invasive & Interventional Department, Cancer Center, Sun Yat-sen University, Guangzhou, China. 4. Department of Diagnostic Radiology, National Cancer Center, Tokyo, Japan. 5. Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China. 6. CHESS Frontier Center, First Hospital of Lanzhou University, Lanzhou, China. 7. Gustave Roussy-Cancer Campus, Villejuif, France. 8. Department of Radiology, Tan Tock Seng Hospital, National University of Singapore, Singapore, Singapore. 9. Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. 10. Department of Radiology and Biomedical Imaging, Section of Interventional Radiology and Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
Abstract
IMPORTANCE: Transarterial chemoembolization (TACE) has been associated with a wide range of practice variations for hepatocellular carcinoma (HCC) between the East and the West. This considerable ambiguity may lead to the heterogeneous quality in treatment and have a negative impact on the role of TACE in the overall multidisciplinary HCC treatment system. OBJECTIVE: It may be a good start to establish a guideline worldwide to have this consensus from experts who represent east and west, although it does not cover all aspects of TACE. EVIDENCE REVIEW: An international expert panel on TACE is convened to cluster the expert's opinions and summary a standard consensus. This panel committee consist of leading physicians in TACE on HCC from USA, France, Japan, Singapore, Korea, China, and so on. The first-round face-to-face consensus meeting was held during in Nanjing, China in October 2019. The second-round conference for revision of the consensus was held during the Annual Meeting of Chinese College of Interventionalists in August 2020 by a hybrid format of a Webinar and roundtable meeting. After several on-line revisions, the final manuscript was approved by all members of the panel in June 2021. FINDINGS: The consensus statements were organized into the following categories: patients' selection, performing the procedure, TACE outcomes, repeat TACE, TACE failure/refractory, and TACE-based combination treatments. CONCLUSIONS AND RELEVANCE FOR REVIEWS: More and more evidences have showed the better outcomes with strategy of combined TACE with other local therapies such as ablations. The most-recently developing strategy of combined TACE with PD-1/PD-L1 plus tyrosine kinase inhibitor (TKI) agents has shined a light to the HCC patients, especially to those with high risk of tumor recurrence after treatment or TACE failure/refractory. 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.
IMPORTANCE: Transarterial chemoembolization (TACE) has been associated with a wide range of practice variations for hepatocellular carcinoma (HCC) between the East and the West. This considerable ambiguity may lead to the heterogeneous quality in treatment and have a negative impact on the role of TACE in the overall multidisciplinary HCC treatment system. OBJECTIVE: It may be a good start to establish a guideline worldwide to have this consensus from experts who represent east and west, although it does not cover all aspects of TACE. EVIDENCE REVIEW: An international expert panel on TACE is convened to cluster the expert's opinions and summary a standard consensus. This panel committee consist of leading physicians in TACE on HCC from USA, France, Japan, Singapore, Korea, China, and so on. The first-round face-to-face consensus meeting was held during in Nanjing, China in October 2019. The second-round conference for revision of the consensus was held during the Annual Meeting of Chinese College of Interventionalists in August 2020 by a hybrid format of a Webinar and roundtable meeting. After several on-line revisions, the final manuscript was approved by all members of the panel in June 2021. FINDINGS: The consensus statements were organized into the following categories: patients' selection, performing the procedure, TACE outcomes, repeat TACE, TACE failure/refractory, and TACE-based combination treatments. CONCLUSIONS AND RELEVANCE FOR REVIEWS: More and more evidences have showed the better outcomes with strategy of combined TACE with other local therapies such as ablations. The most-recently developing strategy of combined TACE with PD-1/PD-L1 plus tyrosine kinase inhibitor (TKI) agents has shined a light to the HCC patients, especially to those with high risk of tumor recurrence after treatment or TACE failure/refractory. 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.
Authors: E Terzi; R Golfieri; F Piscaglia; M Galassi; A Dazzi; S Leoni; E Giampalma; M Renzulli; L Bolondi Journal: J Hepatol Date: 2012-08-04 Impact factor: 25.083
Authors: Karen T Brown; Richard K Do; Mithat Gonen; Anne M Covey; George I Getrajdman; Constantinos T Sofocleous; William R Jarnagin; Michael I D'Angelica; Peter J Allen; Joseph P Erinjeri; Lynn A Brody; Gerald P O'Neill; Kristian N Johnson; Alessandra R Garcia; Christopher Beattie; Binsheng Zhao; Stephen B Solomon; Lawrence H Schwartz; Ronald DeMatteo; Ghassan K Abou-Alfa Journal: J Clin Oncol Date: 2016-02-01 Impact factor: 44.544
Authors: Yun-Bing Wang; Rong Ma; Zhi-Biao Wang; Qiu-Ling Shi; Lian Zhang; Wen-Zhi Chen; Jian-Ping Gong; Jin Bai Journal: Front Oncol Date: 2022-03-28 Impact factor: 6.244